AstraZeneca (AZN) Posts Strong Q1 2026 Results, +8% Revenue Growth Beats Estimates
Key Takeaways
- AstraZeneca reported Q1 2026 total revenue of $15.3 billion, up 8% at constant exchange rates (CER, adjusting for currency fluctuations), beating consensus estimates around $14.8 billion.
- Core earnings per share (EPS) rose 5% to $2.58 at CER, amid a 12% increase in core operating profit.
- Oncology revenue grew 16% to $6.8 billion, while Rare Disease increased 15% to $2.5 billion, driving overall growth.
- Reported profit after tax reached $3.1 billion, with reported EPS at $1.99, up 8% at CER.
- Company reconfirmed FY 2026 guidance: mid-to-high single-digit revenue growth and low double-digit core EPS growth at CER.
- Pipeline progress includes positive Phase III data for four programs since Q4 2025, supporting long-term ambitions.
Earnings Context and Why It Matters
AstraZeneca's Q1 2026 earnings, covering the three months ended March 31, 2026, give us a clear view into how this biopharmaceutical leader is navigating a competitive landscape. With its emphasis on oncology, rare diseases, and biopharmaceuticals, the company has carried forward the momentum from previous quarters, where revenue growth has regularly topped expectations. I always pay close attention to these numbers for clues on key drugs like Tagrisso and Imfinzi, pipeline developments, and margin trends. When results like these come in strong, it reinforces AstraZeneca's approach to innovation and commercial growth, which can impact AZN's valuation and even ripple through to peers in a sector attuned to drug approvals and pricing dynamics.
Reported Results
AstraZeneca posted total revenue of $15,288 million in Q1 2026, coming in ahead of the analyst consensus around $14.8 billion and marking 8% growth at CER compared to Q1 2025. Product sales climbed 7% to $14,386 million, led by Oncology (up 16% to $6,797 million) and Rare Disease (up 15% to $2,475 million), with BioPharmaceuticals up 3% overall.
Core EPS rose 5% to $2.58 at CER, backed by a 12% increase in core operating profit to $5,352 million, even as R&D expenses grew 8% and SG&A rose 7%. Reported EPS came in at $1.99, with profit after tax at $3,081 million. The core tax rate was 21%. CEO Pascal Soriot pointed to this "strong growth" and pipeline highlights, such as Phase III successes for tozorakimab and efzimfotase alfa. The company also stuck to its FY 2026 guidance: mid-to-high single-digit total revenue growth at CER and low double-digit core EPS growth, using 2025 average FX rates. One thing that stands out to me is how these core metrics held up despite the spending increases.
Market Reaction and Investor Sentiment
AZN shares were down 0.4% in the session before the release, but they gained positive traction in early trading after the revenue beat and steady guidance. Investors seem to view the results positively, especially the double-digit gains in Oncology and Rare Disease, which helped offset weaker performance in China. Overall sentiment is upbeat, supported by pipeline advancements against a backdrop of biopharma market swings. From what I see, this positions AZN well heading into the rest of the year.
Tools I Use: Tickeron’s AI Screener
In my own research process, I rely on Tickeron’s AI Screener, an AI-powered tool for discovering stocks and ETFs. It lets me filter thousands of names using criteria like technical patterns, fundamentals, trends, volatility, and AI signals—things like industry, market cap, indicators, price patterns, and performance metrics. This helps me spot trade ideas, breakout candidates, and opportunities far more efficiently than manual scans. I recently used it to compare AZN against its peers, and it's become a go-to for sharpening my analysis.
Forward Outlook and Key Factors to Monitor
The reconfirmed FY 2026 guidance signals AstraZeneca's confidence in ongoing growth, with mid-to-high single-digit revenue increases at CER powered by its broad portfolio. I'm watching execution in growth engines like Oncology and Rare Disease, where new launches and label expansions could build further speed. Pipeline milestones are a big focus, with Phase III readouts expected this year, 14 recent regulatory approvals, and 186 projects in the works overall—building on the four positive Phase III results since Q4 2025.
Cost management matters as R&D ramps up, and we should keep an eye on margin risks from biosimilars and pricing in Emerging Markets, including China's 7% decline. External factors like U.S. drug pricing policies and competition from players like Pfizer and Merck add layers. Events such as roadshows and additional trial data will influence views going forward. Tracking quarterly product sales trends and the core tax rate range of 18-22% will help gauge progress toward those 2030 goals. This is important because it frames the long-term story for investors like us.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Momentum Indicator for AZN turns positive, indicating new upward trend
AZN saw its Momentum Indicator move above the 0 level on June 25, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 79 similar instances where the indicator turned positive. In of the 79 cases, the stock moved higher in the following days. The odds of a move higher are at .
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where AZN's RSI Indicator exited the oversold zone, of 29 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for AZN just turned positive on June 23, 2026. Looking at past instances where AZN's MACD turned positive, the stock continued to rise in of 39 cases over the following month. The odds of a continued upward trend are .
AZN moved above its 50-day moving average on June 25, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where AZN advanced for three days, in of 341 cases, the price rose further within the following month. The odds of a continued upward trend are .
Bearish Trend Analysis
The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AZN declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
AZN broke above its upper Bollinger Band on June 26, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for AZN entered a downward trend on June 26, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 64, placing this stock better than average.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.780) is normal, around the industry mean (19.568). P/E Ratio (26.571) is within average values for comparable stocks, (26.482). Projected Growth (PEG Ratio) (1.349) is also within normal values, averaging (15.849). Dividend Yield (0.018) settles around the average of (0.031) among similar stocks. P/S Ratio (4.560) is also within normal values, averaging (3.939).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. AZN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of pharmaceutical products
Industry PharmaceuticalsMajor
Advertisement